SPECTRE-study

Improved screening of esophageal cancer by optical detection of field cancerization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21436

Enrollment

Registered

2016-03-15

Start date

2016-04-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett's esophagus, esophageal cancer, field cancerization

Interventions

Optical measurements will be performed on several locations in the esophagus. Biopsies will also be obtained. Brush cytology will be obtained.

Eligibility

Inclusion criteria

Inclusion criteria: - Age > 18 years. - Known BE, defined as columnar lined epithelium of the esophagus containing intestinal metaplasia upon biopsy. - Signed informed consent.

Exclusion criteria

Exclusion criteria: - Contraindications for ER and/or obtain biopsies (e.g. due to anticoagulation, coagulation disorders, esophageal varices). - Presence of an advanced lesion (e.g. type 0-I or type 0-III) not amendable for endoscopic resection (T1b). - Presence of erosive esophagitis (Los Angeles classification ¡ÝA). - Unable to provide signed informed consent.

Design outcomes

Primary

Measure	Time frame
The primary objective of our study is to evaluate the feasibility of using MDSFR combined with OCT for the detection of field cancerization in Barrett esophagus patients.	—

Secondary

Measure	Time frame
The secondary objective is to investigate the biological background of field cancerization detected by ESS	—

Contacts

Public ContactJ.J.G.H.M. Bergman

Academic Medical Center Bldg. C2-210, Meibergdreef

j.j.bergman@amc.uva.nl+31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)